Patient Adherence and Disease Management (PH90)
Program Development, Management and Improvement
-
CLICK TO DOWNLOAD
- Published 2006
- 260 Pages
- 400+ Metrics
- 270+ Charts and Diagrams
-
Increase the effectiveness of your patient adherence and disease management programs
This report provides benchmarks for patient adherence and disease management organizational structures, resource investments, tactics and improvement processes. Explore some of the industry's most innovative programs, from leadership involvement to budgets to common program challenges.
Pharmaceutical Patient Adherence and Disease Management is designed in a reader-friendly format so you can easily access information according to interest and need. The report is broken down into four chapters:
Structures, Headcounts and Investment
Learn how industry leaders draw on multiple functions to develop well-rounded campaigns. Explore timing of team assembly and investment levels of various programs.

Program Management
Discover how the most successful programs rely on market research to develop customized messages and launch targeted efforts across various media channels. Study companies' strategies to achieve patient buy-in and overcome program challenges.
Opportunity and Improvement
Investigate the business opportunity of addressing non-adherence. Uncover companies' strategies and tactics to improve their initiatives and the latest innovations on the adherence front.
Real-World Program Details
Analyze real-world programs' resources, compliance rates, development timeframes and media mixes.
Utilize this report to win additional resource support for your patient adherence and disease management efforts. Apply findings from the report to streamline program management and improvement processes.
Back to Top -
Companies Included in Patient Adherence Programs Research
- Amgen
- AstraZeneca
- CVS Pharmacy
- Ferring Pharma
- Genzyme
- Intouch Solutions
- Johnson & Johnson
- Laboratories Sanfer
- Medtronic
- Merck Frosst
- Novartis
- Organon
- NPS Pharmaceutical
- A Pharmaceutical Benefits Manager
- Pfizer
- Amgen
-
Patient Adherence Programs Metrics
The following is a list of metrics included in "Pharmaceutical Patient Adherence and Disease Management." While this list is not inclusive of all the data in the report, it summarizes the main categories and types of data included in each chapter.
Chapter 1:
- Percentage of companies' portfolios supported by patient adherence programs
- Percentage of companies' portfolios supported by disease management programs
- Functions involved in program development and maintenance
- Program team leadership
- Team sizes throughout program launch and maintenance
- Lifecycle stage in which companies assemble program teams
- Percentage of programs' development budgets that are outsourced
- Percentage of companies outsourcing specific program activities
- Investment in program development from concept to implementation
- Annual program maintenance investment
Chapter 2:
- Percentage of companies that have non-branded disease awareness campaigns
- Percentage of companies leveraging various media channels
- Examples of pharmaceutical adherence tools
- Companies' ratings of program challenges
- Percentage of companies with outcome measurements in place to measure ROI
Chapter 3:
- Percentage of average drugs' foregone sales due to adherence issues
- Brand websites most visited by physicians
Chapter 4:
Contains 18 program profiles, which each contain the following metrics and graphics:
- Program background information: condition status, global launch, brand/therapeutic area peak annual sales
- Percentage of patients compliant at various treatment stages
- Cost to attain a new patient vs. cost to retain an existing patient
- Percentage of current overall marketing budget spent on patient adherence/disease management
- Program funding sources
- Development budget vs. annual maintenance budget
- Percentage of development budget spent on various program activities
- Media channels leveraged in campaign
- Percentage of development budget that was outsourced
- Staff support at various program stages
- Timing of key program development activities
- ROI measurements
-
Patient Adherence Programs Report Sample
The following is excerpt was taken from Chapter 2: Program Management
Introduction to Chapter 2
Pharmaceutical companies have been renowned for their large marketing budgets and aggressive drug promotion. Many companies focus their efforts on attaining new patients and securing new scripts for their products. Companies that have a narrow focus, however, overlook a lucrative opportunity to win significant revenues by focusing on retaining their existing patients. Survey data shows that on average it costs a company 38% more to attain a new patient than to retain an existing one. Nonetheless, it seems as though pharmaceutical companies are constantly scrapping for new patients, whilst existing patients are overlooked in the marketing frenzy.
Those companies that take the time to capitalize on the patients they have worked so hard to initially attain will earn significant returns from their efforts. Disease management and patient adherence programs not only make sound business sense for products' bottom lines, but also help bolster the pharmaceutical industry's image. If properly managed these programs can be illustrative of companies' commitment to patients' health as well as promote pharma's social responsibility to healthcare. As healthcare costs skyrocket, pharmaceutical companies can play an important role in helping to alleviate some of these issues through their adherence and disease management programs.
The industry has witnessed pharmaceutical sales forces position themselves to physicians as reliable medical sources in order to provide a useful service and thus receive additional face-time to discuss their portfolios. This same strategy is applicable with non-branded disease management programs. Companies have found that they earn patients' respect by positioning themselves as a sound medical resource and champion of a disease state. Establishing non-branded disease management programs is one way companies are able to demonstrate to patients that they care about patients' health above profits. Patients are drawn to companies that they respect and trust. In this way, non-branded disease management programs act as cause branding for the companies. In fact, 56% of surveyed companies have non-branded disease management programs in place as Figure 2.1 illustrates. These programs have been growing in popularity and more companies will roll out such initiatives in the future.
While non-branded disease management programs continue to grow in popularity, branded patient adherence and disease management initiatives are still the more popular efforts put forth by pharmaceutical companies. This chapter will explore the reasons why companies establish such programs, the goals they aim to achieve, common tactics used to meet program objectives, and how companies overcome inherent challenges of program development and maintenance.
The following is excerpted from Chapter 3: Program Improvement Opportunities
Innovate in Consumer Communications
One of the chief means for improving programs is to explore new channels for communicating with patients. The Internet, or electronic channel, has emerged in the last decade as a critical tool that allows for direct interaction between consumers and companies.
Many interviewees, however, discussed their companies' slowness to adopt web-based tools in adherence and disease management programs. An interviewee at Company D feels the organization has not done enough to take advantage of web opportunities.
A team leader at Company H echoes this opinion by saying "companies are stuck in the dark ages in some respects. They think print a lot, and they don't realize how many consumers look for health information on the web."
Although an increased web presence may help to bolster program effectiveness, teams must still employ the channels that consumers favor. Company D's interviewee notes that programs often work with elderly populations that are less computer-savvy than younger patients.
Overall, programs adjust their channels to best communicate with patients. When teams explore new means for communicating with patients, such as via cell phones or web-based interactivity, they also monitor results to ensure that the new channel is meeting customer needs.
Newer technologies do play a role in delivering both disease management- and compliance-oriented messages to patients. One mid-sized company considered the following tools in its effort to create a balanced set of communication channels:
- Website to present disease and product information
- Emails focused on disease or condition
- Emails focused on product
- Surveys to engage patients and improve program
- Test messaging focused on compliance
- Call center to handle inbound calls
- Call center to handle outbound calls
- Emails focused on compliance
- Desktop reminder tools focused on compliance
- RSS feeds focused on compliance
- Calendar stickers focused on compliance







